{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:16:04Z","timestamp":1794024964495,"version":"4.8.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03502-7","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:58:47Z","timestamp":1791925127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-Drug Conjugate Manufacturing: Facility Design, Process Safety, and Regulatory Considerations"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7670-3158","authenticated-orcid":false,"given":"Ashley","family":"Harp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"3502_CR1","doi-asserted-by":"publisher","unstructured":"Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti\u2010Cancer Association; Expert Committee for Monitoring the Clinical Application of Antitumor Drugs; Breast Cancer Expert Committee of National Cancer Quality Control Center; Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center. Expert consensus on the clinical application of antibody-drug conjugates in the treatment of malignant tumors (2021 edition). Cancer Innov. 2022 Jun 19;1(1):3\u201324. https:\/\/doi.org\/10.1002\/cai2.8.","DOI":"10.1002\/cai2.8"},{"issue":"6","key":"3502_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3502_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.25071","volume":"38","author":"A Darbandi","year":"2024","unstructured":"Darbandi A, Abdi M, Dashtbin S, Yaghoubi S, Sholeh M, Kouhsari E, et al. Antibody-antibiotic conjugates: a comprehensive review on their therapeutic potentials against bacterial infections. J Clin Lab Anal. 2024;38(10):e25071. https:\/\/doi.org\/10.1002\/jcla.25071.","journal-title":"J Clin Lab Anal"},{"key":"3502_CR4","doi-asserted-by":"publisher","unstructured":"McPherson MJ, Hobson AD, Hernandez A Jr, Marvin CC, Waegell W, Goess C, Oh JZ, Shi D, Hayes ME, Wang L, Wang L, Schmidt D, Wang Z, Pitney V, McCarthy K, Jia Y, Wang C, Kang BN, Bryant S, Mathieu S, Ruzek M, Parmentier J, D'Cunha RR, Pang Y, Phillips L, Brown NJ, Xu J, Graff C, Tian Y, Longenecker KL, Qiu W, Zhu H, Liu W, Zheng P, Bi Y, Stoffel R. An anti-TNF-glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases. Sci Transl Med. 2024 Mar 20;16(739):eadd8936. https:\/\/doi.org\/10.1126\/scitranslmed.add8936.","DOI":"10.1126\/scitranslmed.add8936"},{"issue":"2","key":"3502_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/abt\/tbaf005","volume":"8","author":"L Wen","year":"2025","unstructured":"Wen L, Zhang Y, Sun C, Wang SS, Gong Y, Jia C, et al. Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development. Antib Ther. 2025Mar 9;8(2):99\u2013110. https:\/\/doi.org\/10.1093\/abt\/tbaf005.","journal-title":"Antib Ther"},{"key":"3502_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64675-6","volume":"16","author":"L Huang","year":"2025","unstructured":"Huang L, Qin G, Gong C, et al. Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs. Nat Commun. 2025;16:9687. https:\/\/doi.org\/10.1038\/s41467-025-64675-6.","journal-title":"Nat Commun"},{"key":"3502_CR7","doi-asserted-by":"publisher","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173\u201385. https:\/\/doi.org\/10.1248\/cpb.c18-00744.","DOI":"10.1248\/cpb.c18-00744"},{"key":"3502_CR8","doi-asserted-by":"publisher","unstructured":"Rosner S, Valdivia A, Hoe HJ, Murray JC, Levy B, Felip E, et al. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress. Am Soc Clin Oncol Educ Book. 2023May;43:e389968. https:\/\/doi.org\/10.1200\/EDBK_389968.","DOI":"10.1200\/EDBK_389968"},{"key":"3502_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar A, Sunildutt NP, Ahmed F, et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother. 2023;161:114408. https:\/\/doi.org\/10.1016\/j.biopha.2023.114408.","journal-title":"Biomed Pharmacother"},{"key":"3502_CR10","unstructured":"EudraLex: The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Annex 1: Manufacture of Sterile Medicinal Products\u2019, August 2022."},{"key":"3502_CR11","unstructured":"EudraLex: The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Annex 15: Qualifications and Validation\u2019, March 2015."},{"key":"3502_CR12","unstructured":"https:\/\/www.gov.uk\/guidance\/international-council-for-harmonisation-of-technical-requirements-for-pharmaceuticals-for-human-use-guidelines."},{"key":"3502_CR13","unstructured":"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/international-council-harmonisation.html."},{"key":"3502_CR14","unstructured":"International Organization for Standardization, ISO 45001O:2018 Occupational health and safety management systems \u2013 Requirements with guidance for use, Edition 1, 2018, https:\/\/www.iso.org\/standard\/63787.html."},{"key":"3502_CR15","unstructured":"Barle EL, Walsh A. Are high potency active pharmaceutical ingredients (HPAPI) also high risks for cross-contamination? Chimica Oggi \u2013 Chemistry Today 35(6). 2017 November\/December https:\/\/www.researchgate.net\/publication\/322477695_Are_high_potency_active_pharmaceutical_ingredients_HPAPI_also_high_risks_for_cross-contamination."},{"key":"3502_CR16","unstructured":"Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) Legislation \u2013 ECHA, echa.europa.eu, echa.europa.eu\/regulations\/reach\/legislation."},{"key":"3502_CR17","unstructured":"\u201cRevised K-REACH \u2013 The Act on the Registration and Evaluation of Chemicals \u2013 Regulatory News \u2013 Chemicals \u2013 CIRS Group,\u201d www.cirs-group.com."},{"key":"3502_CR18","unstructured":"Global Product Compliance (GPC). Actionable Summary China MEE order. 12, https:\/\/gpcregulatory.com\/download\/Actionable%20summary%20-%20China%20MEE.pdf."},{"key":"3502_CR19","unstructured":"ISPE Good Practice Guide: Containment for Potent Compounds. Section 2.6."},{"key":"3502_CR20","unstructured":"29 CFR \u00a7 1910.1200 Occupational Safety and Health Standards Hazard Communication, Code of Federal Regulations, Occupational Safety and Health Administration."},{"key":"3502_CR21","unstructured":"29 CFR \u00a7 1910.134 Occupational Safety and Health Standards. Respiratory Protection, Code of Federal Regulations, Occupational Safety and Health Administration."},{"key":"3502_CR22","unstructured":"DIRECTIVE 2014\/27\/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 26 February 2014 amending Council Directives 92\/58\/EEC, 92\/85\/EEC, 94\/33\/EC, 98\/24\/EC and Directive 2004\/37\/EC of the European Parliament and of the Council, in order to align them to Regulation (EC) No 1272\/2008 on classification, labelling and packaging of substances and mixture."},{"key":"3502_CR23","unstructured":"Regulation (EC) No 1272\/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67\/548\/EEC and 1999\/45\/EC, and amending Regulation (EC) No 1907\/2006 (CLP)."},{"key":"3502_CR24","unstructured":"Council Directive of 27 November 1980 on the protection of workers from the risks related to exposure to chemical, physical and biological agents at work (80\/1107\/EEC). Available at:\u00a0http:\/\/data.europa.eu\/eli\/dir\/1980\/1107\/1995-01-01."},{"key":"3502_CR25","unstructured":"Council Directive 98\/24\/EC of 7 April 1998 on the protection of the health and safety of workers from the risks related to chemical agents at work (fourteenth individual Directive within the meaning of Article 16(1) of Directive 89\/391\/EEC). Available at:\u00a0https:\/\/osha.europa.eu\/en\/legislation\/directive\/directive-9824ec-risks-related-chemical-agents-work."},{"key":"3502_CR26","unstructured":"Directive 2004\/37\/EC of the European Parliament and of the Council of 29 April 2004 on the protection of workers from the risks related to exposure to carcinogens, mutagens or reprotoxic substances at work (Sixth individual Directive within the meaning of Article 16(1) of Council Directive 89\/391\/EEC). Available at:\u00a0https:\/\/osha.europa.eu\/en\/legislation\/directive\/directive-200437ec-carcinogens-or-mutagens-work."},{"key":"3502_CR27","unstructured":"42 CFR \u00a7 84 National Institute for Occupational Safety and Health, Approval of Respiratory Protective Devices. Code of Federal Regulations, National Institute for Occupational Safety and Health."},{"key":"3502_CR28","unstructured":"Occupational Safety and Health Administration. Identifying Hazard Control Options: The Hierarchy of Controls Available at: https:\/\/www.osha.gov\/sites\/default\/files\/Hierarchy_of_Controls_02.01.23_form_508_2.pdf."},{"key":"3502_CR29","unstructured":"International Society of Pharmaceutical Engineers. ISPE Good Practice Guide: SMEPAC Standardized Methodology for the Evaluation of Pharmaceutical Airborne Particle Emissions from Containment Systems, December 2024."},{"key":"3502_CR30","unstructured":"EN 689. (2018) Workplace exposure\u2014measurement of exposure by inhalation to chemical agents\u2014strategy for testing compliance with occupational exposure limit values. Bruxelles, Belgium: European Committee for Standardization EN 689:2018, https:\/\/www.en-standard.eu\/din-en-689-workplace-exposure-measurement-of-exposure-by-inhalation-to-chemical-agents-strategy-for-testing-compliance-with-occupational-exposure-limit-values-includes-amendment-2019\/?srsltid=AfmBOopE0fRZvFe_WyRBerYovL3D9kDnOnpV3oXyACgORmgtlJ_WWCWc."},{"key":"3502_CR31","unstructured":"Council Directive 89\/391\/EEC of 12 June 1989 on the introduction of measures to encourage improvements in the safety and health of workers at work."},{"key":"3502_CR32","unstructured":"International Code Council. International Building Code. Falls Church, Va. International Code Council, as adopted."},{"key":"3502_CR33","unstructured":"National Research Council of Canada. National Building Code of Canada, as adopted."},{"key":"3502_CR34","unstructured":"Ministry of Land, Infrastructure, Transport and Tourism (MLIT). The Building Standard Law of Japan. (Act No. 201 of 1950; Act No. 43 of 2020) https:\/\/www.japaneselawtranslation.go.jp\/en\/laws\/view\/4024\/en."},{"key":"3502_CR35","unstructured":"Hasegawa Tomohiro. Building Control in Japan Part C. Ver. 1910.\u00a0https:\/\/www.iibh.org\/kijun\/pdf\/BCinJ_Part_C_1910.pdf."},{"key":"3502_CR36","unstructured":"Brazilian National Standards Organization (ABNT). Code of Works and Buildings. LAW NO. 6,138, OF APRIL 26, 2018 https:\/\/www.sinj.df.gov.br\/sinj\/Norma\/94156cc83d524f1ba6d0c0555ec9cd9d\/Lei_6138_26_04_2018.html."},{"key":"3502_CR37","unstructured":"City Department of Urban Planning (SEHAB). C\u00f3digo de Obras e Edifica\u00e7\u00f5es \u2013 COE (Code of Public Works for Sao Paulo). https:\/\/prefeitura.sp.gov.br\/web\/licenciamento\/w\/legislacao\/3258."},{"key":"3502_CR38","unstructured":"Ministry of Housing and Urban Rural Development (MOHURD). GB-50011\u20132010 Code for Seismic Design of Buildings. http:\/\/www.mohurd.gov.cn\/. https:\/\/iisee.kenken.go.jp\/worldlist\/10_China\/China%20GB50011-2010%20(in%20English).pdf."},{"key":"3502_CR39","unstructured":"Ministry of Housing and Urban Rural Development (MOHURD). GB-50009\u20132012 Load Code for the Design of Building Structures. http:\/\/www.mohurd.gov.cn\/"},{"key":"3502_CR40","unstructured":"Ministry of Ecology and Environment. GB-50016\u20132014 Code for Fire Protection Design of Buildings. 1998 https:\/\/english.mee.gov.cn\/Resources\/laws\/envir_elatedlaws\/200710\/t20071009_109956.shtml."},{"key":"3502_CR41","unstructured":"International Code Council. International Building Code, Chapter 2, Section 202. Falls Church, Va. International Code Council, as adopted."},{"key":"3502_CR42","unstructured":"United Nations. Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Rev. 11, Geneva, Switzerland, 2025."},{"key":"3502_CR43","unstructured":"International Code Council. International Fire Code, Appendix Table E104.2. Falls Church, Va. :International Code Council, as adopted."},{"key":"3502_CR44","unstructured":"29 CFR \u00a7 1910.119 Occupational Safety and Health Standards: Process safety management of highly hazardous chemicals. Code of Federal Regulations, Occupational Safety and Health Administration."},{"key":"3502_CR45","unstructured":"Directive 1999\/92\/EC of the European Parliament and of the Council of 16 December 1999 on minimum requirements for improving the safety and health protection of workers potentially at risk from explosive atmospheres (15th individual Directive within the meaning of Article 16(1) of Directive 89\/391\/EEC).\u00a0(ATEX 137 \/ ATEX Workplace Directive).\u00a0https:\/\/eur-lex.europa.eu\/eli\/dir\/1999\/92\/."},{"key":"3502_CR46","unstructured":"CSA Group (formerly the Canadian Standards Association). Canadian Electrical Code, as adopted. CSA Group."},{"key":"3502_CR47","unstructured":"National Fire Protection Association (NFPA). NFPA 70\u00ae, National Electrical Code\u00ae (NEC\u00ae), as adopted."},{"key":"3502_CR48","unstructured":"CAN\/CSA C22.2 No. 61010\u20131\u201312, Rev May 11, 2012. Safety Requirements for Electrical Equipment for Measurement, Control and Laboratory Use \u2013 Part 1: General Requirements \u2013 Third Edition."},{"key":"3502_CR49","unstructured":"CAN\/CSA-C22.2 No 60079\u20130:19 Explosive Atmospheres \u2013 Part 0: Equipment \u2013 General Requirements."},{"key":"3502_CR50","unstructured":"CAN\/CSA-C22.2 No 60079\u201311:14 Explosive Atmospheres \u2013 Part 11: Equipment protection by intrinsic safety \u201ci\u201d."},{"key":"3502_CR51","unstructured":"UL 61010\u20131, 3rd ed, Rev May 11, 2012. Safety Requirements for Electrical Equipment for Measurement, Control and Laboratory Use \u2013 Part 1: General Requirements \u2013 Third Edition."},{"key":"3502_CR52","unstructured":"International Electrotechnical Commission (IEC). IEC 61010\u20131:2010 Safety requirements for electrical equipment for measurement, control, and laboratory use - Part 1: General requirements. https:\/\/webstore.iec.ch\/en\/publication\/4279."},{"key":"3502_CR53","unstructured":"ANSI\/UL 60079\u20130:2020 Electrical Apparatus for Explosive Gas Atmospheres \u2013 Part 0: General."},{"key":"3502_CR54","unstructured":"ANSI\/UL 60079\u201311:13 Electrical Apparatus for Explosive Gas Atmospheres \u2013 Part 11: Intrinsic safety \u201ci\u201d."},{"key":"3502_CR55","unstructured":"International Electrotechnical Commission (IEC). IEC 60529 Degrees of protection provided by enclosures (IP code): IP 65. Consolidated Version. https:\/\/webstore.iec.ch\/en\/publication\/2452."},{"key":"3502_CR56","unstructured":"EN 12941:2023. Respiratory protective devices - Powered filtering devices incorporating a loose fitting respiratory interface - Requirements, testing, marking."},{"key":"3502_CR57","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4236\/aces.2023.134025","volume":"13","author":"KK Hotha","year":"2023","unstructured":"Hotha KK. The ABC of ADCs (antibody-drug conjugates): a comprehensive review of technical, regulatory, and clinical challenges. Adv Chem Eng Sci. 2023;13:363\u201381. https:\/\/doi.org\/10.4236\/aces.2023.134025.","journal-title":"Adv Chem Eng Sci"},{"key":"3502_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104865","volume":"215","author":"F Liu","year":"2025","unstructured":"Liu F. Safety assessment of antibody-drug conjugates: nonclinical toxicology, non-active ingredients, and environmental risk considerations. Crit Rev Oncol Hematol. 2025;215:104865. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104865. (ISSN 1040-8428).","journal-title":"Crit Rev Oncol Hematol"},{"key":"3502_CR59","unstructured":"ICH Q9 International Council for Harmonization (ICH), ICH Harmonized Tripartite Guideline, Quality Risk Management \u2013 Q9 Revision 1, May 2023, www.ich.org."},{"key":"3502_CR60","unstructured":"21 CFR \u00a7 211.42 Food & Drug Administration, Department of Health and Human Services: Current Good Manufacturing Practice for Finished Pharmaceuticals Subpart C - Buildings & Facilities. Code of Federal Regulations, Food & Drug Administration."},{"key":"3502_CR61","volume-title":"ISPE Baseline Guide Volume 7: Risk-Based Manufacture of Pharmaceutical Products","author":"International Society of Pharmaceutical Engineers","year":"2017","unstructured":"International Society of Pharmaceutical Engineers. ISPE Baseline Guide Volume 7: Risk-Based Manufacture of Pharmaceutical Products. International Society of Pharmaceutical Engineers; 2017."},{"key":"3502_CR62","unstructured":"Ohsiek, Fred (2023) Stage 1: High Potent Active Pharmaceutical Ingredient (HPAPI) Cleaning Validation (CV). KENX Insight, Volume 3, Article 10, July 2023, https:\/\/kenx.org\/wp-content\/uploads\/2023\/08\/STAGE-1-HIGH-POTENT-ACTIVE-PHARMACEUTICAL-INGREDIENT-CLEANING-VALIDATION_Ohsiek-1.pdf."},{"key":"3502_CR63","volume-title":"ISPE good practice guide: containment for potent compounds","author":"International Society of Pharmaceutical Engineers","year":"2022","unstructured":"International Society of Pharmaceutical Engineers. ISPE good practice guide: containment for potent compounds. International Society of Pharmaceutical Engineers; December 2022."},{"key":"3502_CR64","unstructured":"CRB.\u00a0CRB Horizons 2023 Report, 2023. CRB.\u00a0Available at: https:\/\/go.crbgroup.com\/2023-horizons-life-sciences-report?utm_campaign=Horizons+Life+Sciences+Fall+2023&utm_source=Press+Release."},{"key":"3502_CR65","unstructured":"CRB.\u00a0CRB Horizons 2024 Report, 2024. CRB.\u00a0Available at: https:\/\/go.crbgroup.com\/horizons-life-sciences-2024."},{"key":"3502_CR66","unstructured":"Directive 2014\/34\/EU of the European Parliament and of the Council of 26\u00a0February 2014 on the harmonisation of the laws of the Member States relating to equipment and protective systems intended for use in potentially explosive atmospheres (ATEX 114 \/ ATEX Equipment Directive) .https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:32014L0034."},{"key":"3502_CR67","volume-title":"Tanklager-Richtlinien fur die Chemische Industrie (TRCI)","author":"Basler Chemishe Industrie (BCI)","year":"2009","unstructured":"Basler Chemishe Industrie (BCI). Tanklager-Richtlinien fur die Chemische Industrie (TRCI). Basler Chemishe Industrie (BCI); 2009."},{"key":"3502_CR68","volume-title":"NFPA 400: hazardous materials code","author":"National Fire Protection Association","year":"2019","unstructured":"National Fire Protection Association. NFPA 400: hazardous materials code. Quincy, MA: NFPA; 2019."},{"key":"3502_CR69","volume-title":"NFPA 1: fire code","author":"National Fire Protection Association","year":"2024","unstructured":"National Fire Protection Association. NFPA 1: fire code. Quincy, MA: NFPA; 2024."},{"key":"3502_CR70","unstructured":"National Research Council of Canada. National Fire Code of Canada, as adopted. https:\/\/nrc.canada.ca\/en\/certifications-evaluations-standards\/codes-canada\/codes-canada-publications\/national-fire-code-canada-2025."},{"key":"3502_CR71","unstructured":"National Fire Protection Association,\u00a0\u201cNFPA 13: Standard for the Installation of Sprinkler Systems,\u201d NFPA, Quincy, MA,\u00a0www.nfpa.org\/13\u00a0(2019)."},{"key":"3502_CR72","unstructured":"International Code Council. International Fire Code. Falls Church, Va. :International Code Council, as adopted."},{"key":"3502_CR73","unstructured":"Lake Havasu City Council. IFC Ch. 57 Flammable & Combustible Liquids [FL\/CL] (Addendum) 2012 International Fire Code Checklist. Rev 03\/11\/2020. Lake Havasu City, Arizona. https:\/\/www.lhcaz.gov\/docs\/default-source\/department-documents\/hazmat-flammable-combustible-liquids-checklist.pdf?sfvrsn=9b21c77c_2."},{"key":"3502_CR74","unstructured":"Ausschuss f\u00fcr Gefahrstoffe (AGS). TRGS 510 (Dezember 2020) Lagerung von Gefahrstoffen in ortsbeweglichen Beh\u00e4ltern GMBl 2021 S. 178\u2013216 [Nr. 9\u201310] (vom 16.02.2021) (Committee on Hazardous Substances. (AGS). TRGS 510 Technical Rules for Hazardous Substances - Storage of hazardous substances in non-stationary containers), Ausschuss f\u00fcr Gefahrstoffe (AGS)."},{"key":"3502_CR75","unstructured":"International Code Council. International Building Code, Table 307.1(1). Falls Church, Va. International Code Council, as adopted."},{"key":"3502_CR76","unstructured":"International Code Council. International Building Code, Table 414.5.1. Falls Church, Va. International Code Council, as adopted."},{"key":"3502_CR77","unstructured":"National Research Council of Canada. National Fire Code of Canada Table 3.2.7.1. Small Quantity Exemptions for Dangerous Goods. 2025."},{"key":"3502_CR78","unstructured":"National Research Council of Canada. National Fire Code of Canada Table 3.2.7.6. Separation Chart for Storage of Dangerous Goods. 2025."},{"key":"3502_CR79","unstructured":"International Code Council. International Building Code, Table 307.1(2). Falls Church, Va. International Code Council, as adopted."},{"key":"3502_CR80","unstructured":"International Code Council. International Mechanical Code. Falls Church, Va. :International Code Council, as adopted."},{"key":"3502_CR81","unstructured":"International Code Council. International Plumbing Code. Falls Church, Va. :International Code Council, as adopted."},{"key":"3502_CR82","unstructured":"Council Directive 92\/58\/EEC of 24 June 1992 on the minimum requirements for the provision of safety and\/or health signs at work (ninth individual Directive within the meaning of Article 16 (1) of Directive 89\/391\/EEC)."},{"key":"3502_CR83","unstructured":"International Council for Harmonization (ICH), Guidance for Industry, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients \u2013 Q7 Revision 1 (ICH Q7), United States Food and Drug Administration, September 2016, https:\/\/www.fda.gov\/files\/drugs\/published\/Q7-Good-Manufacturing-Practice-Guidance-for-Active-Pharmaceutical-Ingredients-Guidance-for-Industry.pdf."},{"key":"3502_CR84","unstructured":"International Council for Harmonization (ICH), Guidance for Industry, Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological\/Biological Entities) (ICH Q11), International Council for Harmonization, 2012."},{"key":"3502_CR85","unstructured":"EudraLex: The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Annex 2:\u00a0Manufacture of Biological active substances and Medicinal Products for Human Use, June 2018."},{"key":"3502_CR86","unstructured":"International Council for Harmonization (ICH), Guidance for Industry, Quality of Biotechnological Products \u2013 Q5A-Q5E (ICH Q5A-Q5E), United States Food and Drug Administration"},{"key":"3502_CR87","unstructured":"International Council for Harmonization (ICH), Draft Guidance for Industry, Implementation Considerations for FDA-Regulated Products (ICH Q12), May 2021, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ich-q12-implementation-considerations-fda-regulated-products."},{"key":"3502_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070957","volume":"11","author":"Y Wang","year":"2019","unstructured":"Wang Y, Fan S, Xiao D, Xie F, Zhong W, Zhou X-B. Novel silyl ether-based acid-cleavable antibody-MMAE conjugates with appropriate stability and efficacy. Cancers (Basel). 2019;11:957. https:\/\/doi.org\/10.3390\/cancers11070957.","journal-title":"Cancers (Basel)"},{"key":"3502_CR89","doi-asserted-by":"publisher","unstructured":"Graham JC, Hillegass J, Schulze G. Considerations for setting occupational exposure limits for novel pharmaceutical modalities. Regul Toxicol Pharmacol. 2020 Dec;118:104813. https:\/\/doi.org\/10.1016\/j.yrtph.2020.104813.","DOI":"10.1016\/j.yrtph.2020.104813"},{"key":"3502_CR90","unstructured":"Allen J. Ebens, Jr., San Carlos, CA (US); Frederic S. Jacobson, Berkeley, CA (US); Paul Polakis, Burlingame, CA (US); Ralph H. Schwall, Pacifica, CA (US); Mark X. Sliwkowski, San Carlos, CA (US); Susan D. Spencer, Tiburon, CA (US). Antibody Drug-Conjugates and Methods. United States Patent. US 8,652.479 B2. 2014."},{"key":"3502_CR91","doi-asserted-by":"publisher","unstructured":"Lentz TJ, Seaton M, Rane P, Gilbert SJ, McKernan LT, Whit taker C. Technical report: The NIOSH occupational exposure banding process for chemical risk management. NIOSH [2019]. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2019\u2013132, https:\/\/doi.org\/10.26616\/NIOSHPUB2019132.","DOI":"10.26616\/NIOSHPUB2019132"},{"key":"3502_CR92","unstructured":"ISPE Good Practice Guide: Containment for Potent Compounds. Section 3.5."},{"key":"3502_CR93","unstructured":"Occupational Safety and Health Administration (OSHA), Assigned Protection Factors for the Revised Respiratory Protection Standard, OSHA 3352\u201302 2009."},{"key":"3502_CR94","doi-asserted-by":"publisher","unstructured":"Gairola A, Hilaly AK, Karim MN. Modeling and Optimization of Antibody-drug Conjugate Production Using Process Intensified Solid PhaseMethod \u2013 J. ADC. February 17, 2020. https:\/\/doi.org\/10.14229\/jadc.2020.02.001.","DOI":"10.14229\/jadc.2020.02.001"},{"key":"3502_CR95","unstructured":"Immunogen, Inc et al. WO2006086733 \u2013 Process for Preparing Maytansinoid Antibody Conjugates. International Patent Application. PCT\/US2006\/004937."},{"key":"3502_CR96","unstructured":"GMP around the World: How the US, EU, Japan, China, Brazil, EAEU, and WHO compare. https:\/\/www.adrispharma.com\/insights\/gmp-around-the-world-how-the-us-eu-japan-china-brazil-eaeu-and-who-compare."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03502-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:41:05Z","timestamp":1793025665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":96,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3502"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03502-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to add the collection title as the sub-category and to include the editorial responsibility information above authors affiliation.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although the author endeavors to provide accurate and timely information, there is no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation.","order":1,"name":"Ethics","label":"Legal Notice","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author was an employee and stockholder of CRB at the time when the work was performed. The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"326"}}